S&P 500   4,008.01 (-0.39%)
DOW   32,223.42 (+0.08%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
S&P 500   4,008.01 (-0.39%)
DOW   32,223.42 (+0.08%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
S&P 500   4,008.01 (-0.39%)
DOW   32,223.42 (+0.08%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
S&P 500   4,008.01 (-0.39%)
DOW   32,223.42 (+0.08%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
NASDAQ:ALT

Altimmune (ALT) Stock Forecast, Price & News

$4.81
-0.35 (-6.78%)
(As of 05/16/2022 04:00 PM ET)
Add
Compare
Today's Range
$4.78
$5.17
50-Day Range
$3.94
$7.50
52-Week Range
$3.83
$19.46
Volume
733,521 shs
Average Volume
804,857 shs
Market Capitalization
$207.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.45
30 days | 90 days | 365 days | Advanced Chart
Receive ALT News and Ratings via Email

Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter.

Altimmune logo

About Altimmune

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALT
Employees
47
Year Founded
N/A

Sales & Book Value

Annual Sales
$4.41 million
Book Value
$5.01 per share

Profitability

Net Income
$-97.09 million
Net Margins
-2,819.11%
Pretax Margin
-2,201.61%

Debt

Price-To-Earnings

Miscellaneous

Free Float
41,862,000
Market Cap
$207.90 million
Optionable
Optionable

Company Calendar

Last Earnings
5/12/2022
Today
5/16/2022
Next Earnings (Estimated)
8/09/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.26 out of 5 stars

Medical Sector

300th out of 1,423 stocks

Pharmaceutical Preparations Industry

116th out of 678 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













Altimmune (NASDAQ:ALT) Frequently Asked Questions

Is Altimmune a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Altimmune stock.
View analyst ratings for Altimmune
or view top-rated stocks.

When is Altimmune's next earnings date?

Altimmune is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Altimmune
.

How were Altimmune's earnings last quarter?

Altimmune, Inc. (NASDAQ:ALT) announced its quarterly earnings results on Thursday, May, 12th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.13. Altimmune had a negative trailing twelve-month return on equity of 41.69% and a negative net margin of 2,819.11%. During the same quarter in the prior year, the firm earned ($0.38) earnings per share.
View Altimmune's earnings history
.

When did Altimmune's stock split? How did Altimmune's stock split work?

Altimmune shares reverse split on the morning of Friday, September 14th 2018. The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of Altimmune stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for ALT?

6 analysts have issued 1-year price objectives for Altimmune's shares. Their forecasts range from $21.00 to $34.00. On average, they anticipate Altimmune's stock price to reach $27.57 in the next year. This suggests a possible upside of 473.2% from the stock's current price.
View analysts' price targets for Altimmune
or view top-rated stocks among Wall Street analysts.

Who are Altimmune's key executives?
Altimmune's management team includes the following people:
  • Dr. Vipin K. Garg Ph.D., Pres, CEO & Director (Age 64, Pay $869.46k)
  • Mr. Richard I. Eisenstadt M.B.A., Chief Financial Officer (Age 64, Pay $120k)
  • Dr. M. Scot Roberts Ph.D., Chief Scientific Officer (Age 63, Pay $564.87k)
  • Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS, Chief Medical Officer (Age 69, Pay $614.11k) (LinkedIn Profile)
  • Mr. Bertrand Georges Ph.D., Chief Technology Officer
  • Mr. José Ochoa, Chief Bus. Officer
What other stocks do shareholders of Altimmune own?
What is Altimmune's stock symbol?

Altimmune trades on the NASDAQ under the ticker symbol "ALT."

Who are Altimmune's major shareholders?

Altimmune's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.79%), Vanguard Group Inc. (4.20%), Woodline Partners LP (1.96%), Citigroup Inc. (1.83%), State Street Corp (1.60%) and Renaissance Technologies LLC (0.90%). Company insiders that own Altimmune stock include Klaus Schafer, Matthew Scott Harris, Philip Hodges and Venrock Healthcare Capital Par.
View institutional ownership trends for Altimmune
.

Which institutional investors are selling Altimmune stock?

ALT stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Citigroup Inc., BlackRock Inc., GSA Capital Partners LLP, Northern Trust Corp, AdvisorNet Financial Inc, Dimensional Fund Advisors LP, and ProShare Advisors LLC.
View insider buying and selling activity for Altimmune
or view top insider-selling stocks.

Which institutional investors are buying Altimmune stock?

ALT stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Woodline Partners LP, Canada Pension Plan Investment Board, JPMorgan Chase & Co., Vanguard Group Inc., Beirne Wealth Consulting Services LLC, Parkman Healthcare Partners LLC, and DCF Advisers LLC. Company insiders that have bought Altimmune stock in the last two years include Klaus Schafer, and Venrock Healthcare Capital Par.
View insider buying and selling activity for Altimmune
or or view top insider-buying stocks.

How do I buy shares of Altimmune?

Shares of ALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Altimmune's stock price today?

One share of ALT stock can currently be purchased for approximately $4.81.

How much money does Altimmune make?

Altimmune has a market capitalization of $207.90 million and generates $4.41 million in revenue each year. The company earns $-97.09 million in net income (profit) each year or ($2.420010) on an earnings per share basis.

How many employees does Altimmune have?

Altimmune employs 47 workers across the globe.

What is Altimmune's official website?

The official website for Altimmune is altimmune.com.

How can I contact Altimmune?

Altimmune's mailing address is 910 CLOPPER ROAD SUITE 201S, GAITHERSBURG MD, 20878. The company can be reached via phone at (240) 654-1450, via email at [email protected], or via fax at 410-269-2601.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.